Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease

Thorax

Volumn 55, Issue 3, 2000, Pages 194-197

  Sin, Don D ^a,c   Tu, Jack V ^a,b  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Ipratropium; Mortality

Indexed keywords

BRONCHODILATING AGENT; IPRATROPIUM BROMIDE;

AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ASTHMA; BRONCHODILATOR AGENTS; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; HUMANS; IPRATROPIUM; LUNG DISEASES, OBSTRUCTIVE; MALE; RETROSPECTIVE STUDIES; RISK; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034095929     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.55.3.194     Document Type: Article

References (15)

1. 1 Speizer FE. The rise in chronic obstructive pulmonary disease mortality: overview and summary. Am Rev Respir Dis 1989;140(Suppl):106-7.
2. 2 Feinlieb M, Rosenberg HM, Collins JG, et al. Trends in COPD morbidity and mortality in the United States. Am Rev Respir Dis 1989;140(Suppl):9-18.
3. 3 Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6.
4. 4 Suissa S, Ernst P, Boivin J, et al. A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists. Am J Respir Crit Care Med 1994;149:604-10.
5. 5 Gross NJ. Ipratropium bromide. N Engl J Med 1988;319: 486-94.
6. 6 The Combivent Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997;112:1514-21.
7. 7 The COPD Guidelines Group of the Standards of Care Committee of the British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52(Suppl 5):1-28.
8. 8 Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. NHLBI/WHO Workshop report. National Institutes of Health, National Heart, Lung and Blood Institute, Publication No. 95-3659, 1995.
9. 9 Guite HF, Dundas R, Burney PGJ. Risk factors for death from asthma, chronic obstructive pulmonary disease and cardiovascular disease after a hospital admission for asthma. Thorax 1999;54:301-7.
10. 10 Meir CR, Jick H. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. Thorax 1997;52:616-7.
11. 11 Rawson NS, Malcolm E. Validity of the recording of ischemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. Stat Med 1995;14:2627-43.
12. 12 Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-29.
13. 13 Tu JV, Pashos CL, Naylor CD, et al. Use of cardiac procedures and outcomes in elderly patients with myocardial infarction in the United States and Canada. N Engl J Med 1998;336:500-5.
14. 1. The Lung Health Study. JAMA 1994;272:497-505.
15. 15 Rennard SI, Serby CW, Ghafouri M, et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest 1996;110:62-70.